Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 6/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.51 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.51 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29854164 | 1.00 | CHRNB2 (0.51) | CHRNB2CHRNA4CHRNB4CHRNA3LMNA | |
| Trifluoroacetic Acid SCHEMBL30901022 | 0.83 | CYP3A4 (0.51) | CHRNB2CHRNA4CHRNB4CHRNA3LMNA | |
| SCHEMBL2485031 | 0.83 | CHRNB2 (0.49) | CHRNB2CHRNA4CHRNB4CHRNA3LMNA | |
| SCHEMBL28037256 | 0.83 | CHRNB2 (0.49) | CHRNB2CHRNA4CHRNB4CHRNA3LMNA | |
| SCHEMBL14477064 | 0.83 | CHRNB2 (0.49) | CHRNB2CHRNA4CHRNB4CHRNA3LMNA | |
| SCHEMBL1515202 | 0.83 | CHRNB2 (0.49) | CHRNB2CHRNA4CHRNB4CHRNA3LMNA | |
| SCHEMBL10915953 | 0.80 | CHRNB2 (0.49) | CHRNB2CHRNA4CHRNB4CHRNA3LMNA | |
| SCHEMBL12549630 | 0.80 | CHRNB2 (0.49) | CHRNB2CHRNA4CHRNB4CHRNA3LMNA | |
| SCHEMBL11911979 | 0.80 | CHRNB2 (0.47) | CHRNB2CHRNA4CHRNB4CHRNA3LMNA | |
| SCHEMBL24261146 | 0.79 | CHRNB2 (0.47) | CHRNB2CHRNA4CHRNB4CHRNA3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 209 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080249142-A1 | N-methyl-5-(5-isopropoxy-3-pyridinyl)-4-penten-2-amine p-hydroxybenzoate; compounds can activate nicotinic receptor and can modulate neurotransmitter secretion; neuroprotective agents; side effects reduction; pains; easy to remove impurities; heck coupling reaction; CNS disorders; inflammatory disorders | TARGACEPT, INC. (US) | 2008-10-09 | — | — | US | claimed |
| CN-101068784-A | Hydroxybenzoate salts of metanicotine compounds | TARGACEPT INC (US) | 2007-11-07 | — | — | CN | claimed |
| EP-1814853-A2 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | Targacept, Inc. (US) | 2007-08-08 | — | — | EP | claimed |
| WO-2006053039-A2 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | TARGACEPT, INC. (US) | 2006-05-18 | — | — | WO | claimed |
| EP-0329360-B1 | Pyridine derivatives | ICI PLC (GB) | 1994-08-03 | — | — | EP | claimed |
| US-5166213-A | Antiischemic agents, cardiovascular disorders, antiasthmatics or antiinflammatory agents | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-11-24 | — | — | US | claimed |
| EP-0329360-A2 | Pyridine derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-08-23 | — | — | EP | claimed |
| EP-4318630-B1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS SECONDARY BATTERY | ASAHI CHEMICAL IND (JP) | 2025-10-22 | — | — | EP | disclosed |
| US-12199280-B2 | Non-aqueous secondary battery and non-aqueous electrolyte | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2025-01-14 | — | — | US | disclosed |
| EP-4081523-B1 | SUBSTITUTED BICYCLIC PIPERIDINE DERIVATIVES USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2024-12-25 | — | — | EP | disclosed |
| CN-114901660-B | Substituted bicyclic compounds useful as T cell activators | 百时美施贵宝公司 | 2024-10-15 | — | — | CN | disclosed |
| EP-4415105-A2 | NON-AQUEOUS SECONDARY BATTERY AND NON-AQUEOUS ELECTROLYTE | Asahi Kasei Kabushiki Kaisha (JP) | 2024-08-14 | — | — | EP | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-5248780-A | Thromboxane inhibitors | IMPERIAL CHEMICAL INDUSTRIES, PLC (GB) | 1993-09-28 | — | — | US | disclosed |
| US-5166213-A | Antiischemic agents, cardiovascular disorders, antiasthmatics or antiinflammatory agents | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-11-24 | — | — | US | disclosed |
| EP-0329360-A2 | Pyridine derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-08-23 | — | — | EP | disclosed |
| US-4631339-A | 1,3,5-triazepinones | ELI LILLY AND COMPANY (US) | 1986-12-23 | — | — | US | disclosed |
| US-4514564-A | 7β-(2'-(1\",3\",5\"-Triazepin-4\"-one)-2'-(oxime ether)-acetamido)-3-substituted cephalosporins | ELI LILLY AND COMPANY (US) | 1985-04-30 | — | — | US | disclosed |
| US-4436912-A | 7-[2-(2-Aminooxazol-4-yl)-2-(oximino)acetamido cephalosporin antibiotics and intermediates therefor | ELI LILLY AND COMPANY (US) | 1984-03-13 | — | — | US | disclosed |
| US-4430499-A | 7-[2-(2-Aminooxazol-4-yl)-2-(oximino)acetamido]cephalosporin antibiotics | ELI LILLY AND COMPANY (US) | 1984-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12199280-B2 | Non-aqueous secondary battery and non-aqueous electrolyte | CLK2, TYK2, CLK3 | CHRNB2 748/4885CHRNA4 1620/4885CHRNB4 1451/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | CHRNB2 3217/4885CHRNA4 2950/4885CHRNB4 3299/4885 |
| US-20080249142-A1 | N-methyl-5-(5-isopropoxy-3-pyridinyl)-4-penten-2-amine p-hydroxybenzoate; compounds can activate nicotinic receptor and can modulate neurotransmitter secretion; neuroprotective agents; side effects reduction; pains; easy to remove impurities; heck coupling reaction; CNS disorders; inflammatory disorders | NTRK1, CHRNA10, CHRNB2 | CHRNB2 3/4885CHRNA4 21/4885CHRNB4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.